During the recent session, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)’s traded shares were 2,964,129, with the beta value of the company hitting 1.53. At the last check, the stock’s price was $1.83, reflecting an intraday gain of 3.39% or $0.06. The 52-week high for the CTXR share is $2.9, that puts it down -58.47% from that peak though still a striking +66.12% gain since the share price plummeted to a 52-week low of $0.62. The company’s market capitalization is $247.51 Million, and the average intraday trading volume over the past 10 days was 3.83 Million shares, and the average trade volume was 14.59 Million shares over the past three months.
Citius Pharmaceuticals, Inc. (CTXR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2. CTXR has a Sell rating from none of the analyst(s) out of 2 analysts who have looked at this stock. Neither of the analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 2 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.07.
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Trading Information
Citius Pharmaceuticals, Inc. (CTXR) registered a 3.39% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.61% in intraday trading to $1.86 this Thursday, Apr 08, hitting a weekly high. The stock’s 5-day price performance is 2.81%, and it has moved by 2.81% in 30 days. Based on these gigs, the overall price performance for the year is 79.41%. The short interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is 7.29 Million shares and it means that shorts have 0.5 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 227.87% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $8 respectively. As a result, CTXR is trading at a discount of 337.16% off the target high and 118.58% off the low.
Citius Pharmaceuticals, Inc. (CTXR) projections and forecasts
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 20%. While earnings are projected to return 42% in 2021, the next five years will return 0% per annum.
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)’s Biggest Investors
Citius Pharmaceuticals, Inc. insiders own 9.78% of total outstanding shares while institutional holders control 7.03%, with the float percentage being 7.79%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 27 institutions own stock in it. As of Dec 30, 2020, the company held over 755.12 Thousand shares (or 4.08% of all shares), a total value of $770.22 Thousand in shares.
The next largest institutional holding, with 169.94 Thousand shares, is of HighTower Advisors, LLC’s that is approximately 0.92% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $173.34 Thousand.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Also, the Mutual Funds coming in first place with the largest holdings of Citius Pharmaceuticals, Inc. (CTXR) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2020 indicates that Vanguard Total Stock Market Index Fund owns about 550,720 shares. This amounts to just over 2.97 percent of the company’s overall shares, with a $561.73 Thousand market value. The same data shows that the other fund manager holds slightly less at 204.31 Thousand, or about 1.1% of the stock, which is worth about $208.4 Thousand.